RG-7351
TAAR1 agonist
From Wikipedia, the free encyclopedia
RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.[1][2][3][4] It reached phase 1 clinical trials for this indication in 2010.[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.[1] The drug was developed by Hoffmann-La Roche.[1][2][4]
Other namesRG7351
| Clinical data | |
|---|---|
| Other names | RG7351 |
| Drug class | Trace amine-associated receptor 1 (TAAR1) partial agonist |
See also
- Ralmitaront (RG-7906; RO-6889450)
- RG-7410
- Ulotaront (SEP-363856; SEP-856)
